Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MTI Aims To Rebound From Onyx Trial Delays, Focuses European Business

This article was originally published in The Gray Sheet

Executive Summary

Micro Therapeutics, Inc.'s pivotal study of its Onyx liquid embolic system for the treatment of brain aneurysms will remain on target for completion by the third quarter of 2002, with 138 patients on board as predicted, the firm says

You may also be interested in...



Micro Therapeutics, Inc.

Cerebral Aneurysm Multi-Center European Onyx (CAMEO) trial treats 99% (122 of 123) of aneurysms successfully, firm reports Feb. 13. Liquid embolic device hit European market in January, following MTI distribution partnership with ev3 International. In the U.S., MTI completed 30% of total case requirements for two Onyx trials as of year-end 2001, with enrollment completion targeted for the third quarter of 2002 (1"The Gray Sheet" Nov. 5, 2001, p. 26). The Irvine, California company's sales increased 54% in 2001 to $8.8 mil. A net loss of $20.1 mil. compares with a loss of $11.8 mil. in 2000...

Micro Therapeutics, Inc.

Cerebral Aneurysm Multi-Center European Onyx (CAMEO) trial treats 99% (122 of 123) of aneurysms successfully, firm reports Feb. 13. Liquid embolic device hit European market in January, following MTI distribution partnership with ev3 International. In the U.S., MTI completed 30% of total case requirements for two Onyx trials as of year-end 2001, with enrollment completion targeted for the third quarter of 2002 (1"The Gray Sheet" Nov. 5, 2001, p. 26). The Irvine, California company's sales increased 54% in 2001 to $8.8 mil. A net loss of $20.1 mil. compares with a loss of $11.8 mil. in 2000...

Cordis Trufill Embolic System Approval Is Fledgling Neurovascular Unit's First

Cordis Neurovascular plans to launch the Trufill n-butyl cyanoacrylate (n-BCA) liquid embolic system for treatment of cerebral arteriovenous malformations (AVMs) the week of Oct. 2 following FDA approval of the neurovascular glue Sept. 26.

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel